WisdomTree BioRevolution Fund

WDNA

Valor de mercado US$ 4,46 mi

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

By Christopher Gannatti, CFA, Global Head of Research Key Takeaways In Q1 2025, the WisdomTree Efficient Gold Plus Gold Miners Strategy Fund (GDMN) led all performers, benefiting from a capital-efficient structure that captured gains in both gold futures and gold mining equities amid persistent inflation concerns and geopolitical instability.

Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?

By Christopher Gannatti, CFA Key Takeaways Recent advancements in GLP-1 drugs, such as Ozempic and Wegovy, underscore their potential to transform health care by addressing obesity, cardiovascular diseases and even neurodegenerative conditions.

By Christopher Gannatti, CFA, Global Head of Research We have been writing a lot about artificial intelligence (AI) and the ways in which we believe that topic will continue to evolve as the calendar changes from 2023 to 2024.

It's been a lengthy of stretch of subpar performance by biotech stocks and related exchange traded funds. That's a scenario that will repeat this year.